# Just Biotherapeutics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/just-biotherapeutics

- Industry: Biotechnology
- Headquarters: Seattle, US
- Website: www.justbiotherapeutics.com
- Total disclosed funding: $29M
- Latest round: Series A (Jul 25, 2016)
- Investors on record: 4

## About

Just Biotherapeutics, Inc. is a biotechnology company that specializes in contract development and manufacturing organization (CDMO) services, focusing on biotherapeutics including antibodies and biosimilars.Founded in 2014, Just Biotherapeutics, Inc. is headquartered in Seattle, US, and operates as a CDMO for biotechnology firms. The company was acquired by Evotec SE in May 2019 for USD 90 mn, marking a strategic expansion in Evotec's capabilities. The firm has completed three deals to date.Just - Evotec Biologics specializes in contract development and manufacturing organization (CDMO) services, primarily focusing on the development and cGMP manufacturing of biotherapeutics, including antibodies, next-generation biologics, and biosimilars. Their core offerings include antibody discovery, process development, and biomanufacturing, which leverage advanced continuous manufacturing technologies designed to enhance productivity and reduce costs. These services are aimed at biotechnology and pharmaceutical companies seeking efficient and reliable solutions for their therapeutic development processes. The company operates in multiple geographical markets, including North America and Europe, catering to clients from diverse sectors within the life sciences industry, including emerging biotech firms and established pharmaceutical companies that require scalable manufacturing solutions. Just - Evotec Biologics employs an innovative end-to-end continuous manufacturing platform that optimizes the production and purification of biologics, ensuring high product quality and compliance with regulatory standards.Just - Evotec Biologics operates on a B2B transaction model, primarily engaging with clients through partnership agreements and fee-for-service contracts. The company's revenue structure is built around providing comprehensive solutions that may include co-development opportunities, integrated programs, and technology out-licensing arrangements. Clients are charged based on the services rendered, which encompass early clinical to commercial cGMP biologics manufacturing, as well as analytical and process development services. The pricing structure reflects the complexity and scale of the projects undertaken, with clients benefiting from tailored solutions that meet specific regulatory and quality standards. Just - Evotec Biologics’ flagship offerings, such as their award-winning J.POD facility design and continuous manufacturing processes, serve to enhance their market position and attract a diverse clientele seeking competitive and innovative biotherapeutic manufacturing solutions.In the wake of the acquisition by Evotec in May 2019, Just Biotherapeutics plans to leverage its advanced continuous manufacturing technologies to design new products tailored for emerging markets. The firm aims to expand its operations in Europe and North America, targeting significant growth in these regions by 2023. The recent funding from the acquisition will support the development of innovative biotherapeutic solutions and enhance its manufacturing capabilities.

## Funding rounds

- Series A, Jul 25, 2016, $14M — ARCH Venture Partners, Lilly Asia Ventures, Merck & Co., Inc., Bill and Melinda Gates Foundation
- Series A, Sep 18, 2015, $15M — ARCH Venture Partners, Lilly Asia Ventures, Merck & Co., Inc.

## Investors

- ARCH Venture Partners (https://capitalatlas.ai/funds/arch-venture-partners) — Series A
- Lilly Asia Ventures (https://capitalatlas.ai/funds/lilly-asia-ventures) — Series A
- Merck & Co., Inc. — Series A
- Bill and Melinda Gates Foundation — Series A